Showing 1-10 of 345 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Collaboration for Global T1D Care | Acora | Rebecca Goldman | Mission | 01-December-2025 to 31-January-2027 | $648,500.00 |
| Addressing and mitigating sources of variability for the controlled and automated manufacturing of stem cell-derived beta (SC-beta) cells from pluripotent stem cells (PSCs) | Advanced Regenerative Manufacturing Institute (ARMI) | Thomas Bollenbach | Cures | 01-January-2023 to 31-December-2026 | $1,241,255.20 |
| Production of SC-islets for distribution | Advanced Regenerative Manufacturing Institute (ARMI) | Thomas Bollenbach | Cures | 01-March-2026 to 30-November-2026 | $471,977.53 |
| Repurposing Cardiorenal Drugs for T1D: Building Evidence from Existing Trials (ReCaRD T1D) | AdventHealth | Richard Pratley | Improving Lives | 01-September-2023 to 20-May-2026 | $110,840.00 |
| Telemedicine-Delivered Cognitive Behavioral Therapy to Reduce Diabetes Distress in Young Adults with Type 1 Diabetes (CBT-DD) | Albert Einstein College of Medicine | Jeffrey Gonzalez | Improving Lives | 01-September-2021 to 30-June-2027 | $1,870,600.00 |
| Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression in Young Adults with Type 1 Diabetes | Albert Einstein College of Medicine | Jeffrey Gonzalez | Improving Lives | 01-December-2022 to 30-November-2026 | $1,672,180.00 |
| Evaluating the Initial Efficacy, Acceptability, and Feasibility of BFST-DT, an Intervention for Improving Transition Readiness for Adolescents and Emerging Adults with Type 1 Diabetes | Ann & Robert H. Lurie Children’s Hospital of Chicago | Jaclyn Papadakis | Improving Lives | 01-May-2023 to 30-April-2027 | $396,471.68 |
| A hybrid effectiveness implementation trial of an intervention to reduce diabetes-specific emotional distress. | Ann & Robert H. Lurie Children’s Hospital of Chicago | Jill Weissberg-Benchell | Improving Lives | 01-September-2024 to 31-August-2029 | $1,936,551.00 |
| Oxygen Enabled High-capacity Vascularized Devices for ß-cell Replacement Therapy in Humans | Arizona Board of Regents, University of Arizona | Klearchos Papas | Cures | 01-September-2023 to 31-August-2026 | $2,652,490.70 |
| Towards non-invasive imaging and improvement of islet engraftment via vascularization and oxygenation | Arizona Board of Regents, University of Arizona | Klearchos Papas | Cures | 01-October-2025 to 30-September-2027 | $897,151.29 |